Promacta, Revolade (eltrombopag) is a small molecule pharmaceutical. Eltrombopag was first approved as Promacta on 2008-11-20. It is used to treat aplastic anemia and thrombocytopenic purpura idiopathic in the USA. It has been approved in Europe to treat thrombocytopenic purpura idiopathic. The pharmaceutical is active against thrombopoietin receptor. Promacta's patents are valid until 2027-08-01 (FDA).
|Indication||aplastic anemia, thrombocytopenic purpura idiopathic|
|Drug Class||Thrombopoetin agonists|